AUTL Autolus Therapeutics plc

10.27
+0.2  (+2%)
Previous Close 10.07
Open 10.01
Price To Book 1.72
Market Cap 461,969,022
Shares 44,982,378
Volume 151,272
Short Ratio
Av. Daily Volume 177,438
Stock charts supplied by TradingView

NewsSee all news

  1. Autolus Announces Closing of Public Offering

    LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its

  2. Autolus' Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting

    LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces that the Company's Founder

  3. Autolus Announces Pricing of Public Offering

    LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an

  4. Autolus Announces Proposed Public Offering in the United States

    LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced

  5. Autolus Therapeutics to provide outlook for 2020 at the 38th Annual J.P. Morgan Conference

    LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, is presenting at the 38th Annual J.P.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 interim data due 2H 2020.
AUTO4
T-cell lymphoma
Phase 2 decision on initiation in DLBCL is expected for mid-2020
AUTO3 - (ALEXANDER)
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
Phase 1 data presented at ASH December 8, 2019.
AUTO2
Relapsed or refractory multiple myeloma
Phase 1 data at ASH December 7, 2019 noted 87% MRD negative complete response. Further data due 2020.
AUTO1
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
AUTO5
T-cell lymphoma
Phase 1 data presented at ASH December 2019.
AUTO3 - (AMELIA)
Acute Lymphoblastic Leukemia
Phase 1/2 trial to be initiated 2H 2020.
AUTO6
Neuroblastoma

Latest News

  1. Autolus Announces Closing of Public Offering

    LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its

  2. Autolus' Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting

    LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces that the Company's Founder

  3. Autolus Announces Pricing of Public Offering

    LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an

  4. Autolus Announces Proposed Public Offering in the United States

    LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced

  5. Autolus Therapeutics to provide outlook for 2020 at the 38th Annual J.P. Morgan Conference

    LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, is presenting at the 38th Annual J.P.

  6. Autolus Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    LONDON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian

  7. Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies

    Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL patients dosed with

  8. Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

    AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome   Data presented at 61st American Society of Hematology Annual Meeting form basis for advancement

  9. Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting

    LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET / 1:30 pm GMT to review

  10. Autolus Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

    LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today

  11. Autolus Therapeutics and Noile-Immune Announce Licensing Agreement

    LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune Biotech, Inc.,

  12. Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today

  13. Autolus Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

    LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and

  14. Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting

    LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  15. Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  16. Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  17. Autolus Therapeutics to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7

    LONDON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release

  18. Autolus Announces Changes to Executive Leadership Team

    LONDON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced changes to the

  19. Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that pre-clinical

  20. Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL

    Findings from Phase I CARPALL Trial Demonstrate that Autolus' Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a

  21. Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

    LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will